Anti-cytokine biological therapy in RA

Research output: Contribution to journalArticle

Abstract

Rheumatoid arthritis (RA) is characterized by persistent synovial inflammation, resulting in estruction of joints. It has been demonstrated that the pro-inflammatory cytokines play a pivotal d role in the pathogenesis of RA, raising a hypothesis that the blockade of the cytokine cascade may provide a new therapeutic modalities in the disease. Biological agents inhibiting the function of inflammatory cytokines thus have been developed. Chimeric monoclonal antibody to TNFα(infliximab), full human antibody to TNFα (adalirnumab), TNF receptor 2-IgG fusion protein (etanercept), and IL-1 ra (anakinra) are new approved for RA in the states. In 2003, infliximab has just approved for RA in Japan, and we are now facing with the biological era. In this paper, the recent progress of anti-cytokine biological agents is reviewed.

Original languageEnglish
Pages (from-to)95-102
Number of pages8
JournalDrug Delivery System
Volume19
Issue number2
DOIs
Publication statusPublished - 2004
Externally publishedYes

Fingerprint

Biological Therapy
Rheumatoid Arthritis
Cytokines
Biological Factors
Interleukin 1 Receptor Antagonist Protein
Tumor Necrosis Factor Receptors
Interleukin-1
Japan
Immunoglobulin G
Joints
Monoclonal Antibodies
Inflammation
Antibodies
Proteins
Infliximab
Therapeutics

Keywords

  • IL-1
  • IL-6
  • TNF

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Anti-cytokine biological therapy in RA. / Takeuchi, Tsutomu.

In: Drug Delivery System, Vol. 19, No. 2, 2004, p. 95-102.

Research output: Contribution to journalArticle

@article{e2df32161512481f8e4a8683b7af5174,
title = "Anti-cytokine biological therapy in RA",
abstract = "Rheumatoid arthritis (RA) is characterized by persistent synovial inflammation, resulting in estruction of joints. It has been demonstrated that the pro-inflammatory cytokines play a pivotal d role in the pathogenesis of RA, raising a hypothesis that the blockade of the cytokine cascade may provide a new therapeutic modalities in the disease. Biological agents inhibiting the function of inflammatory cytokines thus have been developed. Chimeric monoclonal antibody to TNFα(infliximab), full human antibody to TNFα (adalirnumab), TNF receptor 2-IgG fusion protein (etanercept), and IL-1 ra (anakinra) are new approved for RA in the states. In 2003, infliximab has just approved for RA in Japan, and we are now facing with the biological era. In this paper, the recent progress of anti-cytokine biological agents is reviewed.",
keywords = "IL-1, IL-6, TNF",
author = "Tsutomu Takeuchi",
year = "2004",
doi = "10.2745/dds.19.95",
language = "English",
volume = "19",
pages = "95--102",
journal = "Drug Delivery System",
issn = "0913-5006",
publisher = "Japan Society of Drug Delivery System",
number = "2",

}

TY - JOUR

T1 - Anti-cytokine biological therapy in RA

AU - Takeuchi, Tsutomu

PY - 2004

Y1 - 2004

N2 - Rheumatoid arthritis (RA) is characterized by persistent synovial inflammation, resulting in estruction of joints. It has been demonstrated that the pro-inflammatory cytokines play a pivotal d role in the pathogenesis of RA, raising a hypothesis that the blockade of the cytokine cascade may provide a new therapeutic modalities in the disease. Biological agents inhibiting the function of inflammatory cytokines thus have been developed. Chimeric monoclonal antibody to TNFα(infliximab), full human antibody to TNFα (adalirnumab), TNF receptor 2-IgG fusion protein (etanercept), and IL-1 ra (anakinra) are new approved for RA in the states. In 2003, infliximab has just approved for RA in Japan, and we are now facing with the biological era. In this paper, the recent progress of anti-cytokine biological agents is reviewed.

AB - Rheumatoid arthritis (RA) is characterized by persistent synovial inflammation, resulting in estruction of joints. It has been demonstrated that the pro-inflammatory cytokines play a pivotal d role in the pathogenesis of RA, raising a hypothesis that the blockade of the cytokine cascade may provide a new therapeutic modalities in the disease. Biological agents inhibiting the function of inflammatory cytokines thus have been developed. Chimeric monoclonal antibody to TNFα(infliximab), full human antibody to TNFα (adalirnumab), TNF receptor 2-IgG fusion protein (etanercept), and IL-1 ra (anakinra) are new approved for RA in the states. In 2003, infliximab has just approved for RA in Japan, and we are now facing with the biological era. In this paper, the recent progress of anti-cytokine biological agents is reviewed.

KW - IL-1

KW - IL-6

KW - TNF

UR - http://www.scopus.com/inward/record.url?scp=85010106218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010106218&partnerID=8YFLogxK

U2 - 10.2745/dds.19.95

DO - 10.2745/dds.19.95

M3 - Article

AN - SCOPUS:85010106218

VL - 19

SP - 95

EP - 102

JO - Drug Delivery System

JF - Drug Delivery System

SN - 0913-5006

IS - 2

ER -